NOVO — November 2021
-
Novo Q3: Ozempic slår forventningerne og løfter diabetesforretning https://proinvestor.com/investornyt/728585/novo-q3-ozempic-slar-forventningerne-og-lofter-diabetesforretning-ny
-
Novo OVERBLIK Q3: GLP-1 og fedmemedicin løfter salget markant https://www.proinvestor.com/investornyt/728592/novo-overblik-q3-glp-1-og-fedmemedicin-lofter-salget-markant
-
Novo/CEO: Vil kunne møde efterspørgsel efter Wegovy tidligt i 2022 -NY https://www.proinvestor.com/investornyt/728659/novo-ceo-vil-kunne-mode-eftersporgsel-efter-wegovy-tidligt-i-2022-ny
-
Novo: Oversigt over analytikernes ændringer efter kvartalsregnskab https://www.proinvestor.com/investornyt/729624/novo-oversigt-over-analytikernes-aendringer-efter-kvartalsregnskab
-
Verdens ledere er samlet i Glasgow og regnskabsæsonen er i fuld gang. Lyt med til afsnit 90 af #Investeringspodcasten med Hansen & Larsen, hvor de ser på regnskaber fra bl.a. Ørsted, Vestas, Coloplast og Pandora og kommer ind på COP26 samt ugens gode nyheder fra Teva https://www.proinvestor.com/index.php?p=debat_1&postid=98298.
-
TA-VIDEO med Novo: https://www.proinvestor.com/boards/98300
-
Wegovy
demonstrated significant and sustained weight loss in two-year study in adults with obesity
https://www.proinvestor.com/index.php?p=debat_1&postid=98349 -
Novo/Sydbank: Wegovy-data peger på at man skal blive i behandlingen https://www.proinvestor.com/investornyt/730991/novo-sydbank-wegovy-data-peger-pa-at-man-skal-blive-i-behandlingen
-
Novo/CFRA: Kursmål hæves til 675 kr. fra
580 kr https://www.proinvestor.com/investornyt/731719/novo-cfra-kursmal-haeves-til-675-kr-fra-580-kr -
Novo/HSBC: Løfter kursmålet men ser stadig negativt potentiale https://www.proinvestor.com/investornyt/733301/novo-hsbc-lofter-kursmalet-men-ser-stadig-negativt-potentiale
-
Novo/Goldman: Hæver kursmål til 822 kr. og gentager "køb" https://www.proinvestor.com/investornyt/734096/novo-goldman-haever-kursmal-til-822-kr-og-gentager-kob
-
Novo/UBS: Kursmål løftes til 725 kr. fra 630 kr. - GENT https://www.proinvestor.com/investornyt/734793/novo-ubs-kursmal-loftes-til-725-kr-fra-630-kr-gent
-
Novo Nordisk Gets Label Extension Recommendation for Ozempic in Europe https://www.proinvestor.com/investornyt/734896/novo-nordisk-gets-label-extension-recommendation-for-ozempic-in-europe
-
super novo dage!
-
Novo/Carnegie: Kursmål hæves til 850 kr. fra 722 kr. https://www.proinvestor.com/investornyt/737379/novo-carnegie-kursmal-haeves-til-850-kr-fra-722-kr
-
Novo Nordisk Sales Growth Could Exceed 11% Next Year, Carnegie Says https://www.proinvestor.com/investornyt/737422/novo-nordisk-sales-growth-could-exceed-11-next-year-carnegie-says
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind